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Table 1
M (SD) Range
Percentage of prescribed doses taken 70.39 (21.47) 28.21 e 92.50
Percentage of days with correct
number of doses taken
55.43 (23.11) 20.51 e 88.18
Percentage of days with partial
adherence (1 - 99%)
26.75 (17.18) 8.18 e 56.82
Percentage of days with no prescribed
doses taken
17.81 (22.59) 0 e 64.10
Length of medication interruptions
( 24 hours between doses), days
4.46 (7.45) 0 e 36
Table 1
NIH Consensus Project Ancillary Therapy and Supportive Care Recommen-
dations for Eye GVHD and BFS Survey 1 Results
Therapy Indication/Severity
N with
GVHD
who
tried
Mod
success
Sig
success
Topical Mild
Artiﬁcial Tears 44 45% 7%
Viscous ointment/tears NIS N/A N/A
Topical Moderate/severe
Cyclosporine eye drops 35 8% 0%
Topical steroid drops 28 29% 0%
Lacriserts 10 10% 0%
Oral Moderate/severe
Cevimeline NIS N/A N/A
Pilocarpine NIS N/A N/A
Doxycycline 26 23% 0%
Surgical Moderate/severe
Punctual occlusion:
plugs
36 16% 0%
Punctual occlusion:
cautery
20 20% 5%
Partial tarsorrhaphy 5 40% 0%
Eyewear/
environmental
Moderate/severe
Occlusive eye wear NIS N/A N/A
Lid care/warm
compress
NIS N/A N/A
Bandage contact lens 6 33% 0%
Treatment
not widely
available
Moderate/ severe
Autologous serum eye
drops
8 12.5% 12.5%
Gas-permeable contact
lens (Boston scleral
lens prosthesis,
www.bostonsight.org)*
41 17% 76%
NIS indicates, not in survey; N/A indicates, not applicable
* BostonSight PROSE treatment
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adherence. As such, it is important to understand adherence
in this potentially at-risk group. This study is the ﬁrst to
describe patterns of adherence in adolescents who have
undergone HSCT.
Method: Data for this study are from a larger project
examining adherence in pediatric HSCT recipients. Partici-
pants included eight adolescents (ages 12-18) who had
undergone HSCT and their caregivers. Participants used
Medical EventMonitors (MEMS), electronic pill bottles that
report time-stamped indications of bottle openings to track
adherence for the duration of the study (9 mo.), until all oral
medications were discontinued (n ¼ 2), or until the device
was lost/no longer provided for download (n ¼ 2), resulting
in an average of 195.63 monitored days (SD ¼ 119.87 days).
Daily adherence was calculated by dividing the number of
recorded MEMS openings per day by the number of
prescribed doses for that day. The average length of medi-
cation interruptions ( 24 hours between doses) was
calculated for participants prescribed daily medication (n ¼
7). Caregivers provided demographics. Clinical characteris-
tics were obtained via chart review.
Results: Participants were primarily male (63%), Caucasian
(75%), and non-Hispanic (75%). On average, participants were
14.07 years of age (SD ¼ 1.41 years) and received their
transplant at 14.00 years of age (SD ¼ 1.41 years). Adherence
data are presented in Table 1. Participant level data will also
be presented.
Discussion: Overall, participants struggled to adhere to
medication schedules, taking 70% of prescribed doses and
demonstrating perfect adherence on fewer than four out of
seven days per week. Adherence rates are similar to those
observed in other pediatric populations and demonstrate the
importance of routinely assessing adherence in adolescents
who have undergone HSCT.
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Introduction: Approximately 50% of HSCT recipients
develop chronic GVHD and of these 60% suffer from
moderate to severe ocular GVHD. The symptoms of ocular
GVHD (OCGVHD), blurry vision, burning, foreign body
sensation, pain, excessive tearing, and photophobia, have
negative effects on quality of life (QOL). We attempt to
identify opportunities to increase awareness, acceptance,
access to treatment, and care coordination that can improve
QOL in OCGVHD.
Methods: Retrospective review of 2 online surveys con-
ducted by Boston Foundation for Sight (BFS) and keyword
searches of BBMT and PubMed. Survey 1 in 2009 included1127 self-selected respondents from emails sent to 700 BFS
patients and posts on 3 patient websites: Dry Eye Zone, NKCF
and SJS Foundation. 51 reported OCGVHD (BFS patients
N¼41) and 476 dry eye without COGVHD (BFS patients
N¼147). Survey 2 in 2011 included 149 self-selected
respondents from emails to 900 PROSE treatment patients
seen in previous 5 years. 19 reported OCGVHD and 94 dry eye
(also OCGVHD N¼17).
Results: Survey 1 revealed 26% of COGVHD BFS patients ﬁrst
heard about PROSE treatment from an eye doctor, 26% BMT
transplant team, 28% other medical doctors and 20% other
sources; versus 46%, 0%, 1.5%, and 52.5% respectively for dry
eye patients without COGVHD. Table 1 presents respondent
reported experience and success with ancillary and
supportive care recommendations for Eye GVHD from 2006
NIH consensus project. Survey 2 revealed 84% of OCGVHD
reported PROSE devices daily wear. 79% would have pursued
the treatment months or years earlier if possible, and 31% of
these cited lack of awareness of PROSE treatment as
a delaying factor. 11% consulted 6 or more ophthalmologists
before ﬁnding PROSE; 11% 4 or more; and 28% 3 or more.
Search of BBMT database on 6 combinations of the terms
“ocular”, “chronic”, “graft versus host disease” and/or
“GVHD” anywhere in title or body yields 12 citations
including meeting abstracts. Search of PubMed using same
keyword criteria for title only yields 22 citations.
Conclusions: Despite 2006 consensus workshop recom-
mendations, including multi-disciplinary coordinated care
by an ophthalmologist knowledgeable about HCT and GVHD,
we have found that with OCGVHD receive higher level
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a delayed basis. BMT centers are more likely to be a source of
referral than eye care providers. There is now increased
availability of autologous serum, scleral lenses, and PROSE
treatment. Increasing awareness among these BMT clini-
cians, eye care providers, and patients presents an opportu-
nity for impact as far as improvement QOL for HSCT
survivors.213
Integrating Palliative/Supportive Care Concepts in the
Blood and Marrow Transplant Setting
Pamela Rowland. Palliative and Supportive Care, Children's
of Alabama, Birmingham, AL
The availability of Blood and Marrow Transplant (BMT)
can provide hope and possibly life for patients with certain
acute and chronic diseases that have no hope for cure.
Unfortunately treatments that are necessary to achieve
a cure can illicit untoward symptoms that seriously impact
quality of life (QOL). While the goal of treatmentmay be cure,
the challenge of treatment becomes managing the burden of
those symptoms andmaintaining a QOL that makes that cure
worth the journey.
Symptom burden in the transplant setting presents
a challenge to both the patient and the medical team. High
dose chemotherapies with high emetogenic potential can
illicit severe nausea and vomiting both acute and delayed.
Some acute complications of transplant include mucositis,
anorexia, pain, graft versus host disease and immunosup-
pression. Acute symptoms can become chronic. To address
symptom burden it seems logical that the experts in each of
these disciplines, BMT and palliative/ supportive medicine,
should partner to give these patients the best possible
outcome.
Obstacles to excellent palliative/supportive care in the
BMT setting can occur when consults are based on clinician
values, rather than patient needs. Many clinicians mistakenly
believe palliative/supportive care translates to end of life
care. The World Health Organization reports palliative/
supportive care is applicable early in the course of illness, in
conjunction with other therapies that are intended to
prolong life, such as chemotherapy or radiation therapy, and
includes those investigations needed to better understand
and manage distressing clinical complications.
The intent of this paper is to outline a proposal for the
integration of palliative/supportive care concepts in the BMT
setting that can facilitate the transformation of the latest
knowledge into strategies that help to manage the burden of
symptoms in the BMT setting.214
Body Mass Index as an Indicator of Prognosis in Patients
Undergoing Allogeneic Hematopoietic Stem Cell
Transplantation: A Single Institution Experience
Guillermo Jose Ruiz-Delgado, Julia A. Lutz-Presno,
Carlos Alarcon-Urdaneta, Guillermo J. Ruiz-Arguelles. Centro de
Hematologia y Medicina Interna, Clinica Ruiz, Puebla, Mexico
Both obesity and malnutrition are considered risk factors
for complications and increased relapse and nonrelapse
mortality in hematopoietic stem cell transplantation (HSCT).
An inferior outcome after allogeneic HSCT has been reported
in obese adult patients in both allogeneic and autologous
HSCT: Overweight individuals seem to develop more
complications of graft versus host disease and moreinfections than its normal counterparts. Between March
1996 and December 2010, a total of 138 patients received an
allogeneic HSCT in the Centro de Hematología y Medicina
Interna of the Clinica Ruiz. Patients were stratiﬁed according
to pretransplantation body mass index (BMI) values: 17
patients had low BMI, 62 had normal BMI and 59 patients
had high BMI. Median overall survival (OS) for these three
groups were respectively 9, 12 and 22 months. Patients with
a low BMI had a lower OS than those with a normal BMI (58-
month OS of 24% versus 32%), whereas patients with an
increased BMI had a better outcome (median OS of 22
months and 43% OS at 130months) than those with a normal
BMI. Our ﬁndings demonstrate a correlation between pre-
transplantation BMI and posttransplantation survival and
should provide insight into how to better manage nutritional
support for patients undergoing HSCT.215
Factors Impacting Family Decisions to Pursue
Transplantation for Children with Sickle Cell Disease
Amanda L. Thompson 1, Eileen Twohy 1, Jackie Dioguardi 1,
Emily Riehm Meier 2. 1 Children's National Medical Center,
Washington, DC; 2 Division of Hematology, Children's National
Medical Center, Washington, DC
Background: The only cure currently available for sickle cell
disease (SCD) is hematopeotic stem cell transplantation
(HSCT). Barriers preventing widespread application of HSCT
include limited donor pools and lack of family education
about HSCT. To our knowledge, no studies have examined
medical and psychosocial factors that inﬂuence families'
decisions about whether or not to pursue HSCT for their child
with SCD.
Methods: Surveys created by members of the Sickle Cell,
Blood and Marrow Transplantation, and Psychosocial teams
were distributed to family members attending an education
symposium about HSCT for SCD at a large metropolitan
hospital. Surveys were anonymous, optional, and approved
by the Institutional Review Board; participants were entered
into a gift card drawing. On a scale from 0 (“not important at
all”) to 3 (“very important”), participants rated the relative
importance of 17 factors that may impact the decision to
pursue HSCT.
Results: Thirty-four attendees completed surveys; 15% were
parents/guardians of patients who had already had a trans-
plant (n ¼ 5), 73% were parents/guardians of patients who
had not had a transplant (n ¼ 25), and 12% were “other”
family members (n ¼ 4; e.g., aunt, grandmother). Items that
were consistently rated important (i.e., >80% of respondents
rated them “somewhat important,” “important,” or “very
important”) represented multiple domains, including: HSCT-
related risks (e.g., death, infertility, transplant failure, GVHD),
prevention of SCD complications, medical team interactions
(e.g., hematologist recommendation, trust in medical team),
and psychosocial concerns (e.g., emotional strain on patient/
parents, social support). Items not consistently rated
important included ﬁnancial strain, impact on sibling donor,
child losing hair, child missing school, and religious beliefs.
Mean importance ratings were highest for risk of death (M ¼
2.91) and prevention of SCD complications (M ¼ 2.82) and
lowest for religious beliefs (M ¼ .68) and child losing hair
(M ¼ 1.00). See for importance ratings of individual survey
items. There were few differences between ratings of family
members who had been through transplant and those who
had not.
Conclusions: When considering HSCT for SCD, parents and
caregivers report HSCT-related risks, interactions with
